Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperthermic Isolated Limb Perfusion with Melphalan, TNF, and IFN-gamma in Extremity Melanoma
NCT00001296Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 1992
- Modality
- Gene Editing, Gene Silencing, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised trial of tumor necrosis factor-α and interferon gamma-1b in melanoma (2 arms), sponsored by National Cancer Institute. Primary endpoint: Local Response Rate. Started Feb 1992; status: completed.
02
Drugs
tumor necrosis factor-αinterferon gamma-1b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00001296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001296.